# Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

> **NCT01277341** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 601 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Bepotastine Besilate Nasal Spray 2% Twice a day
- **DRUG:** Bepotastine Besilate Nasal Spray 3% Twice a day
- **DRUG:** Bepotastine Besilate Nasal Spray 4% Twice a day
- **DRUG:** Placebo Nasal Spray

## Key facts

- **NCT ID:** NCT01277341
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-05
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01277341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01277341, "Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01277341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*